Pharmacy Practice Sponsored Research
Jeffrey Bishop, PharmD
| Title: | Schizophrenia Pharmacogenetics cognition and symptom response to antipsychotics | |
| Sponsor: | National Institute of Mental Health | |
| Summary: | The purpose of this study is to investigate the relationship between genetic markers and cognitive and symptom outcomes in patients with schizophrenia who are treated with antipsychotic agents |
Adam Bress, PharmD
| Title: | The effect of race and genetic variants on diuretic requirements in patients with systolic heart failure | |
| Sponsor: | American Society of health System Pharmacists (ASHP) | |
| Summary: | To investigate the association between race and genotype and chronic oral loop diuretic dose requirements in patients with systolic heart failure and to examine whether race or genotype influences response to IV loop diuretic therapy in a subset of patients recruited for the study who are hospitalized for ADHF. |
Larisa Cavallari, PharmD
| Title: | Functional and Clinical Significance of the CYP2C9 8 Allelle | |
| Sponsor: | American Heart Association | |
| Summary: | To determine whether the CYP2c9*8 allele is associated with reduced metabolic clearance of warfarin as well as to determine whether this allele affects enzyme activity directly or through linage with the -766T>C or -118T>C variant affecting CYP2C9 expression. |
| Title: | Comprehensive studies of novel SNPs affecting warfarin dose in African Americans | |
| Sponsor: | University of Chicago (National Heart, Lung and Blood Institute) | |
| Summary: | To identify novel variation in several candidate genes that predicts variability in warfarin dose requirements in African Americans as well as examine the functional consequences of individual VKORC1 and CYP2C9 SNPs and haplotypes in an in vitro-based method. Also to investigate the role of associated SNPs on Vitamin K Oxidative Reductase (VKOR) function and warfarin pharmacokinetics in humans. |
Jim Fisher, PharmD
| Title: | Open-label study to assess the safety and tolerability of intravenous carbamazepine as short-term replacement of oral carbamazepine in adult patients with epilepsy | |
| Sponsor: | Lundbeck Inc. | |
| Summary: | This is a phase III, multi-center, open-label study designed to assess the safety and tolerability of an intravenous formulation of carbamazepine in adult patients with epilepsy. This study includes a 27-day Lead-in Period, a Confinement Period (up to 7 days and 6 nights), and a 28-day Follow-up Period. During the confinement period, the subject's oral dose of carbamazepine is replaced by an equivalent intravenous dose. Approximately 105 patients with a minimum of 40 patients taking a high dose of carbamazpine (1600 – 2000 mg/day) will be enrolled across all sites. |
Kristen Goliak, PharmD
| Title: | Medication Monitoring & Safety in Older Adults (MMSOA): A community-based educational outreach program | |
| Sponsor: | Age Options | |
| Summary: | University of Illinois pharmacy faculty and students provide community based health promotion targeting medication safety and awareness in at-risk seniors in the Chicagoland area. Specifically, the program provides for screening, assessment and evaluation of senior medication drug regimens through one-on-one review and evaluation. In addition, we strive to promote Healthy People 2020 goals and empower senior’s to take control of their health through recommended vaccinations, educational topic discussions, using their medications wisely, making positive health care choices and encouraging effective open communication with their physicians. |
Hyun-Young Jeong, PharmD
| Title: | Altered Drug Metabolism in Pregnancy | |
| Sponsor: | National Institute of Child Health Development | |
| Summary: | Over 50% of pregnant women take one or more prescription drugs due to pre-existing or newly developing medical conditions. Despite the prevalent use of medications, how pregnancy alters drug disposition is poorly understood. Accurate pharmacokinetic information is crucial for pregnant women because under or over dose may result in detrimental clinical outcomes in both mother and fetus. Clear understanding of altered drug disposition during pregnancy should enable prediction of pharmacokinetic changes of drugs in pregnant women. The aim of this study is to establish effects of estrogen and PRG and CYP expression and drug metabolism in human hepatocytes as well as determine molecular mechanisms by which expression of two major CYP enzymes, CYP3A4 and CYP2D6 is up-regulated during pregnancy. |
| Title: | Development of PLpro and 3CLpro Protease Inhibitors as Novel SARS Therapeutics (UIC PI: Michael Johnson) | |
| Sponsor: | National Institute of Allergy and Infectious Disease | |
| Summary: | The objective of this project is to develop new antiviral agents for defense against the Severe Acute Respiratory Syndrome Coronavirus (SARSCoV) that was responsible for the 2002 outbreak that produced more than 8,400 confirmed infections with more than 800 reported deaths worldwide and enormous corollary economic damage |
| Title: | Broad-spectrum antibiotic against Category A agents (UIC PI: Michael Johnson) | |
| Sponsor: | Defense Threat Reduction Agency | |
| Summary: | The overall objective of this project is to develop inhibitors of the purine biosynthetic pathway as broad spectrum antibiotic agents with activity against both Gram-positive (B. anthracis) and Gram-negative (F. tularensis and Y. pestis) CDC Category A bacterial pathogens |
Jeremy Johnson, PharmD
| Title: | Mangostin: A Dietary-Based Xanthone for Prostate Cancer Chemoprevention | |
| Sponsor: | National Cancer Institute | |
| Summary: | To determine the oral safety and tolerability of Mangostin as well as to determine the efficacy of Mangostin in the TRAMP model when administered in food pellets. We believe that this proposal incorporates a more traditional drug development model that will be extremely valuable in creating preliminary data about the cancer chemopreventive potential of alpha-Mangostin for prostate cancer. |
Alan Lau, PharmD
| Title: | Identification of markers for determining the efficacy of vitamin D receptor activity therapy in Stage ¾ CKD patients | |
| Sponsor: | Abbott Laboratories | |
| Summary: | Death from heart disease is greater in chronic kidney disease (CKD) and dialysis patients compared to the general population. It may be possible that CKD is linked to heart deaths. Active vitamin D is made in the kidneys. When the kidneys stop working it does not make enough Vitamin D. The purpose of this research is to study how a patients body and their genes respond to vitamin D therapy. This study hopes to find specific indicators in patients which respond to vitamin D. |
Todd Lee, PharmD
| Title: | Clinical Effectiveness Research (CONCERT-CER) | |
| Sponsor: | National Heart, Lung and Blood Institute | |
| Summary: | UIC serves as a subcontract to the University of Chicago and will be responsible for leading the evaluation of the comparative effectiveness of medication therapies in patients with COPD. A research team will examine the relative value of interventions in treatments of patients with COPD. |
Mary Moody, PharmD
| Title: | Update of DHS Drug Interaction System | |
| Sponsor: | State of Illinois Department of Human Services | |
| Summary: | Review and update DHS drug interaction system based upon the current DHS formulary review current literature for clinically significant life threatening, critical, and warning drug-drug, drug food and drug laboratory interactions. Review existing interaction messages incorporating new terminology, added drug/classes and additional medical conditions. |
Edith Nutescu, PharmD
| Title: | Barriers to appropriate Anticoagulation with Warfare in Orthopedic Surgery | |
| Sponsor: | Ortho McNeil Janssen | |
| Summary: | The primary purpose of this study is to explore and describe the barriers and limitations of using traditional anticoagulants (warfarin and LMWH) for thromboprophylaxix after major orthopedic surgery of the lower extremeties (THR and TKR). This study will also conduct a comprehensive literature review to identify and analyze factors that hinder the use of traditional anticoagulants as effective prophylactic agents after MOS. |
Simon Pickard, PhD
| Title: | Takeda Pharmaceuticals International and UIC 2-Year Fellowship in Health Economics and Outcomes (*TWO CONTRACTS ARE ONGOING) | |
| Sponsor: | Takeda Pharmaceuticals | |
| Summary: | The objective of this fellowship is to train independent health outcomes scientists with expertise and skills in health economics and outcomes research that can assume leadership positions in the pharmaceutical industry or academic. The goals of the fellowship are to enable the fellow to collaborate with other scientist to perform clinical, economic and/or humanist outcomes research, to use outcomes research skills to formulate a valid research question and study design, to demonstrate skills and knowledge in various methodologies. |
Keith Rodvold, PharmD
| Title: | Intrapulmonary Pharmacokinetics in Healthy Adult Subjects | |
| Sponsor: | Ortho McNeil Janssen | |
| Summary: | Phase I, multiple dose, single period, open-label pharmacokinetic study conducted in healthy adult male and female subjects as one study center. The pulmonary concentrations or doripenem will be determined and related to the plasma concentrations by performing bronchoscopy with BAL at timed intervals. |
| Title: | Disposition in Cerebrospinal Fluid in Subjects with External Ventriculstomy | |
| Sponsor: | Ortho McNeil Janssen | |
| Summary: | Optimal antibiotic therapy is highly dependent on achieving maximal bacterial concentrations at the site of the infection. Any antibiotic suggested for the treatment of central nervous system infections needs to attain therapeutic concentrations in the cerebrospinal fluid (CSF). Doripenem is a new carbapenem agent with favorable spectrum of activity against the microorganisms commonly associated with nosocomial bacterial meningitis and CSF shunt infections. The primary objective is to estimate the penetration of doripenem into CSF of subjects with an external ventriculostomy. |
Glen Schumock, PharmD
| Title: | Developing Evidence to Inform Decisions about Effectiveness Research Network (DECIDE 2) | |
| Sponsor: | Agency for Healthcare Research and Quality | |
| Summary: | A consortium of Chicago Institutions coordinated by UIC is one of 11 new centers nationwide designated by the Department of Human Services to support research on patient-centered outcomes of health care, with a focus on comparing clinical effectiveness. Among 13 groups initially chosen in 2005 by the Agency for Healthcare Research and Quality, the Chicago group is one of only 8 selected to continue for the second phase of the DEcIDE program, which also includes 3 new centers. The 11 DEcIDE-2 centers will compete among each other for agency projects. |
| Title: | UC/UIC Comparative Effectiveness Research Institutional Career Development Award (KM1) | |
| Sponsor: | University of Chicago | |
| Summary: | The Scholars chosen will participate in didactic and experiential training related to comparative effectiveness research as well as grantwriting, translational research and responsible conduct of research. As part of the Scholar’s professional development, he/she will be expected to propose and carry out a mentored research project and to apply for external research funding such as a NIH/AHRQ R-series grant. |
Daniel Touchette, PharmD
| Title: | Assessment of a Telepharmacy Robotic Medication Dispending Unit in Military Warrior Transition Units | |
| Sponsor: | InRange Systems | |
| Summary: | This study involves the use of an electronic medication management assistant, or EMMA delivery unit, designed to remotely deliver, manage and monitor a patients drug therapy and adherence in the outpatient setting under the guidance of a physician, nurse case and pharmacist. |